ZUMA-8: A Phase 1IStudy of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

ZUMA-8 was the first prospective trial to evaluate the safety of brexucabtagene autoleucel, a CD19-directed autologous CAR T-cell immunotherapy, in patients with R/R chronic lymphocytic leukemia.